Great British Rail Sale 2026 returns with £3 fares — where the cheapest UK train tickets are now
7 January 2026
1 min read

Great British Rail Sale 2026 returns with £3 fares — where the cheapest UK train tickets are now

London, Jan 7, 2026, 06:41 GMT

  • The Great British Rail Sale runs Jan 6-12 with up to 50% off more than 3 million journeys
  • Greater Anglia listed Norwich–London one-way fares from £6, with some routes from £3
  • Some passengers complained online about struggling to find the lowest advertised prices

Train operators launched the Great British Rail Sale this week, offering discounts of up to 50% on selected UK train tickets, with some one-way fares starting at £3.

The timing matters for households watching budgets after Christmas, and for operators trying to fill trains through winter and into early spring. The discounts apply to travel between Jan. 13 and March 25, covering midweek trips as well as some weekend travel. 1

Most offers focus on “Advance” tickets, which lock passengers to a specific train, and “Off-Peak” tickets, which are valid outside the busiest periods. Tickets are limited by route and operator and typically need to be bought several days in advance, National Rail said.

Greater Anglia said it was selling “thousands” of discounted fares across East Anglia, including Norwich to London Liverpool Street for £6 one-way and Southend Victoria to London Liverpool Street for £3. “There is only a limited number, and when they’re gone, they’re gone,” Martin Moran, the operator’s commercial director, said. 2

London North Eastern Railway (LNER) said it was putting 1 million discounted tickets on sale, with selected “Advance” fares including York to Newcastle from £8.35 and London to Edinburgh from £27.85. “We are delighted to be putting one million discounted tickets on sale,” LNER commercial director David Flesher said. 3

Transport Secretary Heidi Alexander has linked the promotion to a wider push to cut travel costs, saying the government had frozen rail fares “for the first time in 3 decades” and wanted cheaper rail travel. 4

Not everyone is convinced the bargains are easy to find. “This is a big con just as usual,” a passenger, Clifford Beeton, wrote on X, The Independent reported, while its travel correspondent said some of the lowest headline fares relied on slower routes and limited allocations. 5

Operators and the government point to past sales as evidence the discounts can spur demand, with officials citing last year’s average savings of about £8 per journey. Critics say cheaper tickets can also end up subsidising trips that would have happened anyway, especially on popular intercity routes.

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
DBS stock tops S$58 as Singapore bank rally rolls on; investors eye Feb 9 results
Previous Story

DBS stock tops S$58 as Singapore bank rally rolls on; investors eye Feb 9 results

Cipla share price slides after USFDA flags Pharmathen: what the Form 483 says
Next Story

Cipla share price slides after USFDA flags Pharmathen: what the Form 483 says

Go toTop